Nakazawa Yozo
Department of Pediatrics, Shinshu University School of Medicine.
Rinsho Ketsueki. 2019;60(9):1351-1357. doi: 10.11406/rinketsu.60.1351.
The adoptive transfer of chimeric antigen receptor (CAR)-modified autologous T cells targeted at the B-cell antigen CD19 is highly effective in patients with relapsed or refractory B-cell malignancies. In Japan, tisagenlecleucel has been approved in March 2019, whereas axicabtagene ciloleucel, lisocabtagene maraleucel, and TBI-1501 have been tested in clinical trials. In addition, allogeneic CD19 CAR T cells from family or third-party donors have been developed for treating B-cell malignancies. Moreover, CAR T-cell therapies for acute myeloid leukemia (AML), T-cell leukemia, and multiple myeloma are still under development. Our group is currently preparing a phase I study on granulocyte macrophage colony-stimulating factor receptor-targeted CAR T cells in pediatric and adult patients with AML.
靶向B细胞抗原CD19的嵌合抗原受体（CAR）修饰的自体T细胞过继性转移，对于复发或难治性B细胞恶性肿瘤患者具有很高的疗效。在日本，tisagenlecleucel于2019年3月获得批准，而axi-cabtagene ciloleucel、lisocabtagene maraleucel和TBI-1501已在临床试验中进行了测试。此外，已开发出来自家族或第三方供体的同种异体CD19 CAR T细胞用于治疗B细胞恶性肿瘤。而且，针对急性髓系白血病（AML）、T细胞白血病和多发性骨髓瘤的CAR T细胞疗法仍在研发中。我们团队目前正在准备一项针对AML儿童和成年患者的、靶向粒细胞巨噬细胞集落刺激因子受体的CAR T细胞的I期研究。
